Niacin for dyslipidemia: Considerations in product selection

American Journal of Health-System Pharmacy

Volumn 60, Issue 10, 2003, Pages 995-1005

  McKenney, James ^a  

^a National Clinical Research Inc   (United States)

Author keywords

Antilipemic agents; Dosage forms; Hyperlipidemia; Mechanism of action; Metabolism; Niacin; Release; Sustained action medications; Toxicity

Indexed keywords

ACETYLSALICYLIC ACID; AMINOTRANSFERASE; APOLIPOPROTEIN B; ATORVASTATIN; CREATINE KINASE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIPOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; ORAL ANTIDIABETIC AGENT; PRAVASTATIN; PROSTAGLANDIN; PROSTAGLANDIN INHIBITOR; SIMVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ANGIOGRAPHY; CARDIOTOXICITY; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; FLUSHING; GASTROINTESTINAL SYMPTOM; GOUT; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERURICEMIA; INSOMNIA; LIVER TOXICITY; MIGRAINE; MYOSITIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; PRURITUS; RASH; REVIEW; RHABDOMYOLYSIS; VERTIGO;

EID: 0038630864     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/60.10.995     Document Type: Review

References (63)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. National Cholesterol Education Program: Adult Treatment Panel III report. Bethesda, MD: National Heart, Lung, and Blood Institute, 2001; NIH publication no. 01-3095.
2. Carlson LA, Hamsten A, Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med. 1989; 226:271-6.
3. Gordon DJ, Probstfield JL, Garrison RJ et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation. 1989; 79:8-15.
4. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA. 1999; 282:2340-6.
5. Guyton JR, Blazing MA, Hagar J et al. Extended-release niacin vs gemfibrozil for the treatment of low levels of highdensity lipoprotein cholesterol. Arch Intern Med. 2000; 160:1177-84.
6. Knopp RH, Ginsberg J, Albers JJ et al. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. Metabolism. 1985; 34:642-50.
7. Dalton TA, Berry RS. Hepatotoxicity associated with sustained-release niacin. Am J Med. 1992; 93:102-4.
8. Carlson LA, Orö L, Östman J. Effect of a single dose of nicotinic acid on plasma lipids in patients with hyperlipoproteinemia. Acta Med Scand. 1968; 183:457-65.
9. Grundy SM, Mok HY, Zech L et al. Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man. J Lipid Res. 1981; 22:24-36.
10. Capuzzi DM, Morgan JM, Brusco OA Jr. et al. Niacin dosing: relationship to benefits and adverse effects. Curr Atheroscler Rep. 2000; 2:64-71.
11. Drood JM, Zimetbaum PJ, Frishman WH. Nicotinic acid for the treatment of hyperlipoproteinemia. J Clin Pharmacol. 1991; 31:641-50.
12. Jin F-Y, Kamanna VS, Kashyap ML. Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells: implication for reverse cholesterol transport. Arterioscler Thromb Vasc Biol. 1997; 17: 2020-8.
13. Piepho RW. The pharmacokinetics and pharmacodynamics of agents proven to raise high-density lipoprotein cholesterol. Am J Cardiol. 2000; 86(suppl):35L-40L.
14. Shepherd J, Packard CJ, Patsch JR et al. Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism. J Clin Invest. 1979; 63:858-67.
15. Knopp RH. Evaluating niacin in its various forms. Am J Cardiol. 2000; 86 (suppl):51L-6L.
16. Rader JI, Calvert RJ, Hathcock JN. Hepatic toxicity of unmodified and timerelease preparations of niacin. Am J Med. 1992; 92:77-81.
17. Figge HL, Figge J, Souney PF et al. Comparison of excretion of nicotinuric acid after ingestion of two controlled release nicotinic acid preparations in man. J Clin Pharmacol. 1988; 28:1136-40.
18. Stein EA, Davidson MH, Dujovne CA et al. Efficacy and tolerability of low-dose simvastatin and niacin, alone and in combination, in patients with combined hyperlipidemia: a prospective trial. J Cardiovasc Pharmacol Ther. 1996; 1:107-16.
19. McKenney JM, Proctor JD, Harris S et al. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. JAMA. 1994; 271:672-7.
20. Gardner SF, Marx MA, White LM et al. Combination of low-dose niacin and pravastatin improves the lipid profile in diabetic patients without compromising glycemic control. Ann Pharmacother. 1997; 31:677-82.
21. Davignon J, Roederer G, Montigny M et al. Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia. Am J Cardiol. 1994; 73:339-45.
22. Brown BG, Zhao X-Q, Chait A et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001; 345:1583-92.
23. Gardner SF, Schneider EF, Granberry MC et al. Combination therapy with lowdose lovastatin and niacin is as effective as higher-dose lovastatin. Pharmacotherapy. 1996; 16:419-23.
24. Knopp RH, Alagona P, Davidson M et al. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism. 1998; 47: 1097-104.
25. Tsalamandris C, Panagiotopoulos S, Sinha A et al. Complementary effects of pravastatin and nicotinic acid in the treatment of combined hyperlipidaemia in diabetic and non-diabetic patients. J Cardiovasc Risk. 1994; 1:231-9.
26. Knopp RH. Drug treatment of lipid disorders. N Engl J Med. 1999; 341:498-511.
27. Luria MH. Effect of low-dose niacin on high-density lipoprotein cholesterol and total cholesterol/high-density lipoprotein cholesterol ratio. Arch Intern Med. 1988; 148:2493-5.
28. Keenan JM, Fontaine PL, Wenz JB et al. Niacin revisited: a randomized, controlled trial of wax-matrix sustainedrelease niacin in hypercholesterolemia. Arch Intern Med. 1991; 151:1424-32.
29. Guyton JR, Goldberg AC, Kreisberg RA et al. Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am J Cardiol. 1998; 82:737-43.
30. Elam MB, Hunninghake DB, Davis KB et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease. The ADMIT study: a randomized trial. JAMA. 2000; 284:1263-70.
31. Grundy SM, Vega GL, McGovern ME et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes. Results of the Assessment of Diabetes Control and Evaluation of the Efficacy of Niaspan Trial. Arch Intern Med. 2002; 162:1568-76.
32. Garg A, Grundy SM. Nicotinic acid as therapy for dyslipidemia in non-insulindependent diabetes mellitus. JAMA. 1990; 264:723-6.
33. Molnar GD, Berge KG, Rosevear JW et al. The effect of nicotinic acid in diabetes mellitus. Metabolism. 1964; 13:181-90.
34. American Society of Health-System Pharmacists. ASHP therapeutic position statement on the safe use of niacin in the management of dyslipidemias. Am J Health-Syst Pharm. 1997; 54:2815-9.
35. Niaspan prescribing information. In: Physicians' desk reference. 56th ed. Montvale, NJ: Medical Economics Co.; 2002:1846-50.
36. Gharavi AG, Diamond JA, Smith DA et al. Niacin-induced myopathy. Am J Cardiol. 1994; 74:841-2.
37. Hill MD, Bilbao JM. Case of the month: February 1999 - 54 year old man with severe muscle weakness. Brain Pathol. 1999; 9:607-8.
38. Reaven P, Witztum JL. Lovastatin, nicotinic acid, and rhabdomyolysis. Ann Intern Med. 1988; 109:597-8.
39. Advicor package insert. Miami, FL: Kos Pharmaceuticals; 2001.
40. Simvastatin package insert. Whitehouse Station, NJ: Merck & Co.; 1999 Aug.
41. Goldberg AC. Clinical trial experience with extended-release niacin (Niaspan): dose-escalation study. Am J Cardiol. 1998; 82:35U-8U.
42. Austin MA, Breslow JL, Hennekens CH et al. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA. 1988; 260:1917-21.
43. McKenney JM, McCormick LS, Schaefer EJ et al. Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia. Am J Cardiol. 2001; 88:270-4.
44. McKenney JM, McCormick LS, Weiss S et al. A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Am J Med. 1998; 104:137-43.
45. Jacobson TA, Chin MM, Fromell GJ et al. Fluvastatin with and without niacin for hypercholesterolemia. Am J Cardiol. 1994; 74:149-54.
46. Wolfe ML, Vartanian SF, Ross JL et al. Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia. Am J Cardiol. 2001; 87:476-9.
47. Frick MH, Elo O, Haapa K et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987; 317:1237-45.
48. Robins SJ, Collins D, Wittes JT et al. Relation of gemfibrozil treatment and lipid levels with major coronary events. VAHIT: a randomized controlled trial. JAMA. 2001; 285:1585-91.
49. BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation. 2000; 102:21-7.
50. Boden WE, Pearson TA. Raising low levels of high-density lipoprotein cholesterol is an important target of therapy. Am J Cardiol. 2000; 85:645-50, A10.
51. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA. 1975; 231: 360-81.
52. Canner PL, Berge KG, Wenger NK et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986; 8:1245-55.
53. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand. 1988; 223:405-18.
54. Blankenhorn DH, Nessim SA, Johnson RL et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987; 257:3233-40.
55. Brown G, Albers JJ, Fisher LD et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990; 323:1289-98.
56. Brown BG, Brockenbrough A, Zhao X-Q et al. Very intensive lipid therapy with lovastatin, niacin, and colestipol for prevention of death and myocardial infarction: a 10-year Familial Atherosclerosis Treatment Study (FATS) follow-up. Circulation. 1998; 98:I-635. Abstract.
57. Simons LA. Treatment of lipids. Implications for the general practitioner. Aust Fam Physician. 1996; 25:1053-9.
58. Berge KG. Side effects of nicotinic acid in treatment of hypercholesteremia. Geriatrics. 1961; 16:416-22.
59. Whelan AM, Price SO, Fowler SF et al. The effect of aspirin on niacin-induced cutaneous reactions. J Fam Pract. 1992; 34:165-8.
60. Jungnickel PW, Maloley PA, Vander Tuin EL et al. Effect of two aspirin pretreatment regimens on niacin-induced cutaneous reactions. J Gen Intern Med. 1997; 12:591-6.
61. Wilkin JK, Wilkin O, Kapp R et al. Aspirin blocks nicotinic acid-induced flushing. Clin Pharmacol Ther. 1982; 31:478-82.
62. Rubins HB, Robins SJ, Collins D et al. Distribution of lipids in 8,500 men with coronary artery disease. Am J Cardiol. 1995; 75:1196-201.
63. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002; 287:356-9.